Blood Loss — Blood Loss Assessment in the Limited Application of Tourniquet During Primary Unilateral TKA
Citation(s)
Adie S, Harris I, Chuan A, Lewis P, Naylor JM Selecting and optimising patients for total knee arthroplasty. Med J Aust. 2019 Feb;210(3):135-141. doi: 10.5694/mja2.12109. Epub 2019 Jan 18.
Cao Z, Guo J, Li Q, Wu J, Li Y Comparison of efficacy and safety of different tourniquet applications in total knee arthroplasty: a network meta-analysis of randomized controlled trials. Ann Med. 2021 Dec;53(1):1816-1826. doi: 10.1080/07853890.2021.1991588.
Dunn CJ, Goa KL Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32. doi: 10.2165/00003495-199957060-00017.
Everhart JS, Sojka JH, Mayerson JL, Glassman AH, Scharschmidt TJ Perioperative Allogeneic Red Blood-Cell Transfusion Associated with Surgical Site Infection After Total Hip and Knee Arthroplasty. J Bone Joint Surg Am. 2018 Feb 21;100(4):288-294. doi: 10.2106/JBJS.17.00237.
Gao FQ, Li ZJ, Zhang K, Sun W, Zhang H Four Methods for Calculating Blood-loss after Total Knee Arthroplasty. Chin Med J (Engl). 2015 Nov 5;128(21):2856-60. doi: 10.4103/0366-6999.168041.
Gross JB Estimating allowable blood loss: corrected for dilution. Anesthesiology. 1983 Mar;58(3):277-80. doi: 10.1097/00000542-198303000-00016. No abstract available.
Kim C, Park SS, Davey JR Tranexamic acid for the prevention and management of orthopedic surgical hemorrhage: current evidence. J Blood Med. 2015 Aug 25;6:239-44. doi: 10.2147/JBM.S61915. eCollection 2015.
Lu Q, Peng H, Zhou GJ, Yin D Perioperative Blood Management Strategies for Total Knee Arthroplasty. Orthop Surg. 2018 Feb;10(1):8-16. doi: 10.1111/os.12361. Epub 2018 Feb 9.
Park JH, Restrepo C, Norton R, Mandel S, Sharkey PF, Parvizi J Common peroneal nerve palsy following total knee arthroplasty: prognostic factors and course of recovery. J Arthroplasty. 2013 Oct;28(9):1538-42. doi: 10.1016/j.arth.2013.02.025. Epub 2013 Apr 4.
Sehat KR, Evans RL, Newman JH Hidden blood loss following hip and knee arthroplasty. Correct management of blood loss should take hidden loss into account. J Bone Joint Surg Br. 2004 May;86(4):561-5.
Singh JA Epidemiology of knee and hip arthroplasty: a systematic review. Open Orthop J. 2011 Mar 16;5:80-5. doi: 10.2174/1874325001105010080.
Tai TW, Lin CJ, Jou IM, Chang CW, Lai KA, Yang CY Tourniquet use in total knee arthroplasty: a meta-analysis. Knee Surg Sports Traumatol Arthrosc. 2011 Jul;19(7):1121-30. doi: 10.1007/s00167-010-1342-7. Epub 2010 Dec 15.
Vaishya R, Chauhan M, Vaish A Bone cement. J Clin Orthop Trauma. 2013 Dec;4(4):157-63. doi: 10.1016/j.jcot.2013.11.005. Epub 2013 Dec 15.
Wang C, Zhou C, Qu H, Yan S, Pan Z Comparison of tourniquet application only during cementation and long-duration tourniquet application in total knee arthroplasty: a meta-analysis. J Orthop Surg Res. 2018 Aug 30;13(1):216. doi: 10.1186/s13018-018-0927-6.
Whittaker JL, Truong LK, Dhiman K, Beck C Osteoarthritis year in review 2020: rehabilitation and outcomes. Osteoarthritis Cartilage. 2021 Feb;29(2):190-207. doi: 10.1016/j.joca.2020.10.005. Epub 2020 Nov 24.
Xu H, Yang J, Xie J, Huang Z, Huang Q, Cao G, Pei F Tourniquet use in routine primary total knee arthroplasty is associated with a higher transfusion rate and longer postoperative length of stay: a real-world study. BMC Musculoskelet Disord. 2020 Sep 18;21(1):620. doi: 10.1186/s12891-020-03623-5.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.